Related Experiment Video
Updated: Nov 2, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.4K
P2Y12 blocker monotherapy after percutaneous coronary intervention.
F W A Verheugt1, P Damman2, S A J Damen2
1Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. f.w.a.verheugt@olvg.nl.
Summary
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) increases bleeding risk. P2Y12 blocker monotherapy significantly reduces major bleeding events compared to DAPT, without increasing ischemic risks.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is crucial for secondary prevention in coronary artery disease (CAD).
- Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 blocker is standard after percutaneous coronary intervention (PCI).
- DAPT increases bleeding risk compared to single antiplatelet therapy.
Purpose of the Study:
- To review current literature on P2Y12 blocker monotherapy as an alternative to DAPT after PCI.
- To evaluate the efficacy and safety of P2Y12 blocker monotherapy in reducing bleeding events.
- To compare P2Y12 blocker monotherapy with DAPT regarding ischemic outcomes.
Main Methods:
- Review of five randomized trials and two meta-analyses involving 32,181 stented patients.
- Comparison of outcomes between DAPT and P2Y12 blocker monotherapy.
- Analysis of major bleeding and ischemic events, including stent thrombosis.
Main Results:
- P2Y12 blocker monotherapy demonstrated a 50-60% reduction in major bleeding compared to DAPT.
- No significant increase in ischemic outcomes, such as stent thrombosis, was observed with P2Y12 blocker monotherapy.
- This approach offers a viable strategy to mitigate bleeding risk post-PCI.
Conclusions:
- P2Y12 blocker monotherapy is a safe and effective strategy for reducing bleeding after PCI.
- This therapeutic option balances the need for antithrombotic protection with a reduced risk of hemorrhage.
- Further research may solidify P2Y12 blocker monotherapy as a preferred strategy in select patient populations.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
792
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
792
01:27Peripheral Artery Disease III: Interprofessional Care
89
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
89
01:28Acute Coronary Syndrome IV: Interprofessional Care
69
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
69
01:27Coronary Artery Disease V: Interprofessional Care
84
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
84
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
85
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
85
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
300
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
300